The combination of aggressive hydration and rectal non-steroidal anti-inflammatory drugs is not superior to rectal non-steroidal anti-inflammatory drugs alone in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis - Cheng, Xiang; Yang, Feixiang; Yang, Xingxin; Zhang, Ning; Li, Xiaoming; Chen, Bo (medRxiv, 2022)
Background endoscopic retrograde cholangiopancreatography (ERCP) can lead to many high-risk complications, of which acute pancreatitis is the most prevalent and serious one. Whether patients who receive prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) need to be combined with aggressive hydration remains controversial.Aim The study was performed to determine whether there is collaborative facilitation between rectal NSAIDs and aggressive hydration in preventing post-ERCP pancreatitis (PEP).Methods We searched all eligible studies on the preventive effects of active rehydration and NSAIDs on PEP from multiple databases including ClinicalTrials, PubMed, CQVIP, Embase, Web of Science, CNKI, Cochrane Library, and Wanfang Data. We performed a meta-analysis of the data related to the incidence of PEP as well as the serious cases including the incidence of severe PEP and mortality.Results This meta-analysis included three published studies of randomized controlled trials with 1110 patients. Our results showed that additional aggressive hydration was not significantly effective for the prevention of PEP in patients who were already receiving rectal NSAIDs (odds ratio [OR], 0.43; 95% confidence interval [CI], 0.12-1.57; P=0.20). With regard to the prevention of serious cases, compared with rectal NSAIDs alone, aggressive fluid hydration combined with rectal NSAIDs did not reduce the morbidity of severe PEP (OR, 0.32; 95% CI, 0.10-1.08; P=0.07), nor did it reduce overall mortality (OR, 0.81; 95% CI, 0.28-2.36; P=0.70).Conclusion Aggressive perioperative hydration combined with rectal NSAIDs was not superior to rectal NSAIDs along in the prevention of PEP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Quality Engineering Project of Anhui Province (No.2020jyxm0898；No.2020jyxm0910,No.2019kfkc334), Clinical research project of Anhui Medical University (No.2020xkj176) and Soft health science research of Anhui province-Major project (No.2020WR01003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.